DJIA 16,654.77 369.26 2.27%
NASDAQ 4,812.71 115.17 2.45%
S&P 500 1,987.66 47.15 2.43%
market minute promo

2.65 -0.07 (-2.57%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ARNA $2.65 -2.57%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.72
Previous Close $2.72
Daily Range $2.60 - $2.75
52-Week Range $2.55 - $6.28
Market Cap $641.9M
P/E Ratio -6.63
Dividend (Yield) $0.00 (0.0%)
Volume 4,205,680
Average Daily Volume 2,725,086
Current FY EPS -$0.50




Drug Makers

Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website:

News & Commentary Rss Feed

Bull Or Bear? Biotech's Post-Earnings Buys and Sells

The breakdown on which companies' numbers are easiest to swallow.

Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session

Orexigen: Contrave Wins Another Sales Week - Don't Bank On Impressive Numbers

Vivus Hovers Near 52-Week Lows - Qsymia Sales Not Helping

The 3 Most Disappointing Drug Launches of All Time

Treatments with huge promise don't always pan out the way you'd expect.

Orexigen- Contrave Sales Win The Week But Still Flatter Than Needed

Arena - Belviq Sales Dip Again. We Have Seen The Peak In 2015

Arena's Smoking Cessation Opportunity

Arena Pharmaceuticals' Belviq Sales Are Better Than They Appear (But They're Still Not Great)

Declining quarter-over-quarter sales look bad, but investors needn't freak out.

Vivus: Qsymia Sales Flat - Investors Need Caution Still

See More ARNA News...

ARNA's Top Competitors

ARNA $2.65 (-2.57%)
Current stock: ARNA
AMGN $155.72 (1.13%)
Current stock: AMGN
GILD $107.99 (0.96%)
Current stock: GILD
BIIB $304.49 (2.09%)
Current stock: BIIB